StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Ajit Mishra, Religare

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byAjit Mishra, ReligareHorizon: NA (inferred Swing (≤2wk))30 Jul 2026via Business Standard Markets

Entry₹2,261.7Inferred
Target₹2,420
Total upside +7.00% (call closed)
Stop loss₹2,180-3.61% risk
Exit₹2,1803 Aug 2026, 9:40 am
Stop-loss hit-3.61%
Follow Ajit Mishra for new calls(21% target hit, 117 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 1 active Swing call on GLENMARKSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 3 Aug 2026
7 supporting2 neutral0 opposing
Supports the BUY call (7)

Glenmark Pharma Q1 profit jumps over 10-fold as India, North America businesses power growth

NewsCnbc-Tv18·31 Jul · 2d ago

(opens in new tab)

Glenmark Pharma Q1 Results: Profit Rises Exponentially To Rs 483 Crore; Revenue Jumps 23%

NewsNdtv-Profit·31 Jul · 2d ago

(opens in new tab)

Glenmark Pharmaceuticals Inc., USA has launched Sugammadex Injection in single-dose vials, available in 200 mg/2mL and 500 mg/5mL strengths.

BSE · Company Update·28 Jul · 5d ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·23 Jul · 1w ago

Glenmark Pharma gets USFDA nod to expand RYALTRIS use to children aged 6-12

NewsCnbc-Tv18·21 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·31 Jul · 2d ago

(opens in new tab)

The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

BSE · Board Meeting·31 Jul · 2d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Ajit Mishra, Religare

Every call and its outcome